• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Institutional Site Licenses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Blogs » The Carlat Psychiatry Blog » Free Sample Resource - Most Common Clinically Significant Drug Interactions in Psychiatry

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

General Psychiatry / Hospital Psychiatry

Free Sample Resource - Most Common Clinically Significant Drug Interactions in Psychiatry

June 6, 2026
Daniel Carlat, MD and Victoria Hendrick, MD
PDF
HFB1e_Cover3D.png
Drug Interactions in Psychiatry | Carlat Psychiatry
Psychopharmacology
Clinical Reference Carlat Publishing

When pressed for time, most clinicians rely on online drug interaction checkers. Here are the most commonly used options:

Free

  • Medscape — reference.medscape.com/drug-interactionchecker
  • Epocrates — www.epocrates.com (registration required)
  • Drugs.com — www.drugs.com/drug_interactions.html

Paid

  • Lexicomp — wolterskluwer.com/en/solutions/lexicomp

Most interactions in psychiatry will not result in a serious outcome. Many, however, may result in decreased efficacy or increased adverse effects — and these can be easily avoided. To understand drug-drug interactions, it helps to revisit some core concepts.

Drugs are substrates of specific enzymes, meaning they rely on specific enzymatic pathways for metabolism. An inhibitor binds more tightly to an enzyme than the usual substrate and prevents the enzyme from doing its job. As a result, the substrate cannot be metabolized as quickly as it otherwise would, and its serum levels become higher than expected. An inducer, by contrast, stimulates the production of extra enzymes. With more enzymes available, the substrate is broken down more rapidly, leading to lower serum drug levels.

Timing is also an important consideration. Inhibition happens quickly — it can occur with the first dose of a medication and can subside within five half-lives of the inhibitor once it is discontinued. Induction, on the other hand, requires the body to synthesize more CYP450 enzymes, a process that can take up to four weeks. This accounts for the delayed auto-induction seen with carbamazepine. For induction to subside, these extra enzymes must also be broken down — a process that could likewise take several weeks.

As a general rule of thumb, any drug prescribed with its inhibitor should be started at half the usual dose and titrated more slowly. A drug prescribed with its inducer may need to be dosed higher after the few weeks it takes for induction to occur. One important exception: when the substrate is a prodrug. Tamoxifen, hydrocodone, and tramadol rely on CYP2D6 to be converted into active metabolites. In the presence of a potent inhibitor such as fluoxetine or paroxetine, patients may experience a drop in therapeutic effect rather than increased effects.

Practical Tips for Quickly Identifying Significant Drug Interactions

  • Identify the 10 drugs you most commonly prescribe and memorize their major drug interactions.
  • Antidepressants, antipsychotics, antibiotics, antiretrovirals, and older anticonvulsants have a high likelihood of significant interactions — be particularly vigilant if your patient is taking any of these.
  • Recognize drugs with a narrow therapeutic window — those for which the toxic dose is not much higher than the therapeutic dose. Commonly used examples include lithium, carbamazepine, warfarin, digoxin, phenytoin, and phenobarbital.
  • Be alert to drugs that cause serious outcomes if blood levels are significantly increased or decreased — including oral contraceptives, lamotrigine, clozapine, tricyclic antidepressants, and warfarin.
  • Drugs with long half-lives — such as diazepam or aripiprazole — can be particularly problematic when involved in drug interactions, since metabolic inhibitors or hepatic dysfunction can make them ultra-long lasting. Use extra caution with new or rarely prescribed drugs, where unreported interactions may not yet have surfaced.
  • The risk of drug interactions can increase exponentially as the number of drugs increases. Setting a threshold to check for interactions is helpful (eg, any patient on three or more drugs).

Most Common Clinically Significant Drug Interactions in Psychiatry

Table 11  ·  Most Common Clinically Significant Drug Interactions in Psychiatry
Clinical Consequence Medications Most Commonly Contributing Comments
Decreased efficacy of psychiatric medications Carbamazepine, St. John's wort, cigarette smoking — strongly induce metabolism and decrease serum levels of many psychotropics Smoking may reduce olanzapine and clozapine levels; carbamazepine can reduce levels of many medications
Decreased efficacy of opioids Potent CYP2D6 inhibitors (paroxetine, fluoxetine, duloxetine, bupropion) prevent conversion of certain opioids (codeine, hydrocodone, oxycodone) to active metabolites, decreasing pain relief Use alternative antidepressants (eg, sertraline, citalopram, escitalopram)
Decreased efficacy of oral contraceptive pills (OCPs) Carbamazepine, St. John's wort, cigarette smoking — strongly induce metabolism and decrease serum levels of OCPs Avoid these medications in women taking OCPs
Increased side effects or toxicity of psychiatric medications The most common and potent CYP450 inhibitors — paroxetine, fluoxetine, duloxetine, bupropion, valproic acid, asenapine, and grapefruit juice — may lead to increased substrate levels and increased side effects or toxicity Adjust dose of substrate or use alternative medications
Serotonin syndrome High doses or combinations of: SSRIs, SNRIs, TCAs, MAOIs, buspirone, dextromethorphan, lithium, tramadol, trazodone Caution patients to report sudden onset of fever, agitation, tremor, sweating, or diarrhea; discontinue offending agents and provide supportive care
QT prolongation Monotherapy or combined therapy with: ziprasidone, thioridazine, TCAs, methadone, and certain cardiac medications and antibiotics (amiodarone, ciprofloxacin, clarithromycin, erythromycin, ketoconazole, quinidine) May lead to potentially fatal arrhythmias; monitor ECG and electrolytes; use alternative medications in patients with borderline or increased QT interval
Increased risk for bleeding Serotonergic antidepressants (SSRIs, SNRIs), especially when combined with anticoagulants (warfarin), antiplatelets (aspirin), or NSAIDs May lead to bruising or minor bleeding (nosebleed, gum bleed); GI bleeds and more severe bleeding also rarely reported; use an alternative in patients at highest risk, such as older adults
Lowered seizure threshold Bupropion, clozapine Use with caution in patients with a history of seizures, electrolyte disturbances, or head trauma; consider concomitant antiepileptic for seizure prophylaxis
Lithium toxicity Lithium combined with NSAIDs, ACE inhibitors, angiotensin II receptor blockers, or diuretics (especially thiazides) Use alternative agents or monitor lithium levels closely and adjust dosing
Anticholinergic delirium Anticholinergics (benztropine, trihexyphenidyl), antihistamines (diphenhydramine, doxylamine), low-potency first-generation antipsychotics (chlorpromazine), olanzapine, clozapine, TCAs, oxybutynin High anticholinergic burden may lead to confusion and delirium, particularly in older patients; minimize use or select alternative medications

Hospital Psychiatry Fact Book, First Edition cover

Get Full Access

Hospital Psychiatry Fact Book

First Edition (2025)  ·  Spiral Bound

This 288-page comprehensive guide is designed to be a valuable resource for professionals working in psychiatric inpatient settings. Whether you're a psychiatrist, nurse, social worker, or any other professional in a multidisciplinary team, this book provides the tools and knowledge needed to navigate the intricacies of inpatient psychiatric care.

Order Now
Try The New AskCarlat AI

Ask any clinical question—our AI responds using only the peer-reviewed, editorially vetted content from Carlat Publishing.

Available In The Carlat Toolkit
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2782224449.jpg
    General Psychiatry

    Gender Affirming Care: Fall of the House of Hopkins

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.